ScoreComparison
Why is Aligos Therapeutics, Inc. ?
1
The company has declared positive results in Mar'2026 after 2 consecutive negative quarters
- NET SALES(HY) Higher at USD 3 MM
- NET PROFIT(HY) Higher at USD -47.53 MM
- RAW MATERIAL COST(Y) Fallen by -136.95% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -36.92%, its profits have risen by 0.9%
3
High Institutional Holdings at 94.91%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 3.05% over the previous quarter.
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 25.41% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -36.92% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Aligos Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aligos Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Aligos Therapeutics, Inc.
-36.92%
-0.74
82.82%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-15.81%
EBIT Growth (5y)
7.07%
EBIT to Interest (avg)
-103.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.15
Sales to Capital Employed (avg)
0.09
Tax Ratio
22.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
94.91%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.77
EV to EBIT
0.38
EV to EBITDA
0.38
EV to Capital Employed
1.60
EV to Sales
-15.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
425.38%
ROE (Latest)
-157.47%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET SALES(HY)
Higher at USD 3 MM
NET PROFIT(HY)
Higher at USD -47.53 MM
RAW MATERIAL COST(Y)
Fallen by -136.95% (YoY
-5What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -84.71 MM
CASH AND EQV(HY)
Lowest at USD 133.04 MM
PRE-TAX PROFIT(Q)
At USD -26.12 MM has Fallen at -24.28%
NET PROFIT(Q)
At USD -26.43 MM has Fallen at -25.41%
Here's what is working for Aligos Therapeutics, Inc.
Net Sales
At USD 3 MM has Grown at 219.04%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 3 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -136.95% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Aligos Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -84.71 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -26.12 MM has Fallen at -24.28%
over average net sales of the previous four periods of USD -21.02 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -26.43 MM has Fallen at -25.41%
over average net sales of the previous four periods of USD -21.08 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 133.04 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
